July 23, 2017 10:03 AM ET

Pharmaceuticals

Company Overview of Zambon Company S.p.A.

Company Overview

Zambon Company S.p.A. manufactures and delivers fine chemical and pharmaceutical products for customers in Italy and internationally. The company offers respiratory solutions comprising medical devices for children and adults breath wellness, and children and family breath protection products; pain management products; women healthcare products that include solutions in the area of urinary pathologies; and Xadago (safinamide) for Parkinson's disease treatment. Its fine chemical products comprise custom synthesis, generics APIs, and generics FDF Dossiers. Zambon Company S.p.A. was founded in 1906 and is based in Bresso, Italy with additional offices in Europe, Asia, and South America. It has ...

Via Lillo del Duca, 10

Bresso, MI 20091

Italy

Founded in 1906

Phone:

39 02 665241

Fax:

39 0266 50 14 92

Key Executives for Zambon Company S.p.A.

Chief Executive Officer
President
Vice President of Business Development
Compensation as of Fiscal Year 2017.

Zambon Company S.p.A. Key Developments

Zambon Company S.p.A. Presents at BIO International Conference 2017, Jun-21-2017 03:45 PM

Zambon Company S.p.A. Presents at BIO International Conference 2017, Jun-21-2017 03:45 PM. Venue: San Diego Convention Center, San Diego, CA 2865, United States. Speakers: Cibele Sabido, Head of Business Development CNS and Other Therapeutic Areas.

Zambon and Newron Pharmaceuticals Launch Parkinson's Disease Treatment Xadago in Portugal

Zambon and its compatriot partner Newron Pharmaceuticals have announced the launch in Portugal of their Parkinson's disease (PD) treatment Xadago (safinamide). The drug has been approved as an add-on to levodopa alone or in combination with other PD drugs for treating patients with mid- to late-stage PD.

Valeo Pharma Inc. and Zambon S.p.A Form Partnership for Parkinson's Disease Treatment Xadago in Canada

Zambon S.p.A. and Valeo Pharma Inc. announced a strategic agreement to commercialize Xadago (safinamide) for the treatment of Parkinson's disease in Canada. Under the terms of the agreement, Valeo Pharma will be responsible for all regulatory, sales and marketing, quality, and distribution activities in Canada. Valeo Pharma will pay Zambon upfront, regulatory and commercial milestone payments as well as royalties on product sales.

Similar Private Companies By Industry

Company Name Region
A. Menarini Industrie Farmaceutiche Riunite Srl Europe
Aboca S.p.A. - Societa Agricola Europe
ACME S.r.l. Europe
Acs Dobfar spa Europe
Agrisana S.R.L. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Zambon Company S.p.A., please visit www.zambongroup.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.